Update on Influenza Virus Surveillance Findings in 2008/09 Season in Northern Hemisphere Who Collaborating Center for Reference and Research on Influenza.

Slides:



Advertisements
Similar presentations
INFLUENZA DIVISION U.S. Influenza Surveillance Update, Season Joseph Bresee, MD Epidemiology and Prevention Branch, Influenza Division, CDC VRBPAC.
Advertisements

INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA Information Regarding Seasonal Influenza Viruses FEBRUARY 27,
INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA (Seasonal Influenza and Zoonotic Influenza) FEBRUARY 28, 2012.
Swine flu.
The pandemic and a brief ABC of influenza Thomas Abraham JMSC 6090.
Wrap-up of Day 1. Plenary One: Regional and Global Update Update of global situation and response to pandemic (H1N1) Dr Wenqing Zhang Regional.
CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION Influenza Surveillance in Mainland of China Yuelong Shu Chinese National Influenza Center National Institute.
Information source: Swine Flu What is Swine Influenza? Swine Influenza (swine flu) is a respiratory disease of pigs caused by type A influenza.
Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.
INFLUENZA. VIROLOGY OF INFLUENZA Subtypes: A - Causes outbreak B - Causes outbreaks C - Does not cause outbreaks.
Bird Flu.  Bird flu, also known as Avian Influenza, is a type A influenza virus. It is fatal to humans. Bird flu spreads between both wild and pet birds.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
About Swine Flu Dr.Kedar Karki. What is Swine Influenza? Swine Influenza (swine flu) is a respiratory disease of pigs caused by type A influenza virus.
Someday in the Spring, an Army private reported to the camp hospital before breakfast. He had a fever, sore, throat, headache... nothing serious. One minute.
Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.
Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.
Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.
INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA FEBRUARY 22, 2010 Nancy J. Cox, Ph. D Director WHO COLLABORATING.
Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.
What should be taken into consideration when establishing antiviral resistance surveillance? Aeron Hurt WHO Collaborating Centre for Reference and Research.
Texas Influenza Surveillance Lesley Bullion Influenza Surveillance Coordinator Infectious Disease Control Unit.
A Brief Update of Global Situation and Response to Pandemic Influenza A(H1N1) 2009 Wenqing Zhang MD Global Influenza Programme WHO HQ THE 3rd MEETING OF.
Martha Thompson, MPH Viral Isolation Team Leader Medical Virology Group Laboratory Services Section TX DSHS Influenza Surveillance Viral Isolation Laboratory.
Update on Influenza A(H5N1) Activity in Asia Nancy J. Cox, Ph.D. Chief, Influenza Branch National Center for Infectious Diseases Centers for Disease Control.
Influenza Vaccine Manufacturing Industry Perspective Tony Colegate Novartis Vaccines and Diagnostics Prepared by PhRMA Vaccine Technical Committee for.
Update of Antiviral Resistance in Seasonal and Pandemic Influenza Viruses 3 rd NIC Meeting, Beijing, China August th 2009 Aeron Hurt WHO Collaborating.
Lessons from the European Experience with A(H1N1) 2009 Angus Nicoll CBE European Centre for Disease Prevention and Control 3 rd meeting of the National.
Review and Discussion Time line courtesy of:
World Health Organization, Regional Office for The Western Pacific Regional Activities Report and Preparation for the Upcoming Influenza Seasons THE 3rd.
Sheila Negrini Parmezan São Paulo, Introduction The neuraminidase inhibitors (NAIs), oseltamivir and zanamivir, are currently the antiviral drugs.
Influenza Branch Division of Viral and Rickettsial Diseases National Center for Infectious Diseases Centers for Disease Control and Prevention Atlanta,
Texas Influenza Surveillance Lesley Bullion Influenza Surveillance Coordinator Infectious Disease Control Unit.
Influenza Today Joseph Mester, Ph.D. September 24, 2009.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.
The Current Season: A Review of the Influenza Season Nancy J. Cox, Ph.D. Chief, Influenza Branch National Center for Infectious Diseases Centers.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
Vaccines and Related Biological Products Advisory Committee Meeting July 23, 2009 Pandemic Influenza A (H1N1) Virology Update Nancy Cox, PhD Alexander.
Avian Influenza H5N1 Prepared by: Samia ALhabardi.
Communicable Disease Surveillance and Response, WHO Avian Influenza Credit: WHO Viet Nam.
Options for Influenza Vaccine Composition Summary of Data Options with Pros and Cons.
1 Division of Health Security and Emergencies (DSE) WHO Western Pacific Regional Office (WPRO) Fifth Meeting of National Influenza Centres in the Western.
1 |1 | Situation Update Influenza A (H1N1), 26 May 09.
Ian Barr WHO Collaborating Centre for Reference & Research on Influenza, Melbourne (Now finally re-located at VIDRL) Influenza surveillance in Australia,
DoD Global, Laboratory-Based Influenza Surveillance Program Sequence Analysis and Vaccine Effectiveness Overview Maj Thomas Gibbons, PhD, Virologist Chris.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
The New Influenza A/H1N1 Isabelle Thomas May 28-29, 2009 Brussels,
(CAREC) PAHO/WHO Serving 21 Member Countries in the English and Dutch Speaking Caribbean 2009 Pandemic Influenza in CAREC Member Countries: Summary and.
Swine Flu & You! Information Regarding the Possible Approaching Swine Flu Pandemic.
Influenza Activity and Virus Characterizations (Northern Hemisphere) 5thMeeting of NICs in the WPR and SEAR 7-10 June, 2011 Laos Takato Odagiri WHO Collaborating.
Influenza Branch VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA February 16-17, 2005, Bethesda, MD Nancy COX, Ph.D. WHO COLLABORATING.
Update on Surveillance for Influenza Viruses with Pandemic Potential and Candidate Vaccine Viruses Nancy Cox, PhD CDC.
1 Influenza activity in the Southern Hemisphere Ian Barr WHO CC for Reference & Research on Influenza Melbourne The Melbourne WHO.
RCGP England: ‘influenza and influenza-like illness’
Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/22/2010) Jerry P. Weir, Ph.D., Director.
INFLUENZA DIVISION Update on the Epidemiology and Clinical Features of Novel H1N1 Joseph Bresee, MD Chief, Epidemiology and Prevention Branch Influenza.
Lisa Grohskopf, MD, MPH U.S. Influenza Surveillance Season National Center for Immunization & Respiratory Diseases Influenza Division U.S. Food.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.
DoD Global Influenza Surveillance Program Sentinel Site Surveillance at AFIOH Sequence Analysis And Vaccine Effectiveness Overview Luke T. Daum, PhD, Molecular.
STATUS OF CANDIDATE VACCINE STRAINS AND POTENCY REAGENTS Zhiping Ye, M.D., Ph.D. FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH.
INFORMATION FOR THE VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE, CEBR, FDA February 27-28, 2007 WHO COLLABORATING CENTER FOR SURVEILLANCE,
Influenza Virologic Surveillance and Vaccine Strain Selection Xiyan Xu MD Deputy Director WHO Collaborating Center for Surveillance, Epidemiology and Control.
The State of Communicable Diseases in Indiana
Overview of the Objectives, Expected Outcomes, and Meeting Agenda
Genetic sequencing pilot project in Latin America
A Web-based Interactive Genome Library for Surveillance, Detection, Characterization and Drug-Resistance Monitoring of Influenza Virus Infection in the.
Virological surveillance of influenza and other respiratory viruses during six consecutive seasons from 2006 to 2012 in Catalonia, Spain  A. Antón, M.A.
NP sequence alignment of human H1N1 strains and phylogenetic analysis of representative NP from pandemic and seasonal H1N1 strains. NP sequence alignment.
J. -H. Lin, S. -C. Chiu, J. -C. Cheng, H. -W. Chang, K. -L. Hsiao, Y
Presentation transcript:

Update on Influenza Virus Surveillance Findings in 2008/09 Season in Northern Hemisphere Who Collaborating Center for Reference and Research on Influenza at Center for Influenza Virus Research, National Institute of Infectious Diseases, Tokyo, Japan Takato Odagiri, Ph.D.

Weekly report of virus isolation/detection in season By NIID By CDC Pandemic A/H1N1 viruses

A(H1N1) viruses September 2008-January 2009

H1N1, Sept 2008 – Jan 2009

H1N1 antigenic analysis By NIID

H1N1 antigenic analysis By CDC

Summary of antigenic analysis of A/H1N1 in four WHO CCs A/Br/59/07-like low-reactors (≥ 8-f) CDC (Oct-) 179 [100%] 0 [0%] NIID (Oct-) 72 [95%] 4 [5%] NIMR (Oct-) 62 [87%] 9 [13%] VIDRL (Oct-) 119 [97.5%] 3 [2.5%] Total 432 [96%] 16 [4%]

March-July 2009

By CDC

By NIMR

Antigenic characterization of AH1N1 viruses isolated after March By NIID By CDC

Number of oseltamivir resistance viruses isolated in Japan ( Oct 2008-May 2009 ) By NIID

H1N1 viruses - Summary Oct 2008-Feb 2009 Influenza A(H1N1) viruses predominated in many Asian and North American countries The majority of viruses were antigenically closely related to A/Brisbane/59/2007 by HI analysis Phylogenetically the majority of H1N1 viruses grouped into the A/Brisbane/59/2007 clade (2B) based on their HA gene. Recent 2B viruses share H275Y indicative of resistance to oseltamivir. They were antigenically similar to osel-sensitive viruses. Recent viruses from China fall within the A/Hong Kong/2652/2006 clade (2C) and these viruses were similar antigenically to clade 2B viruses. Clade 2C viruses are sensitive to oseltamivir and resistant to amantadine/rimantadine Mar - July 2009 The features of viruses were similar to those observed earlier in Majority of recent A(H1N1) viruses were antigenically closely related to A/Brisbane/59/2007 and formed clade 2B sharing H275Y. In the few clade 2C viruses, dual resistance to oseltamivir and amantadine/rimantadine were detected.

A(H3N2) viruses September 2008-January 2009

H3N2, Sept 2008 – Jan 2009

By NIID

By NIMR

A/Brisbane/10/07-like low-reactors (≥ 8-f) CDC (Oct-) 45 [90%] 5 [10%] NIID (Oct-) 32 [56%]25 [44%] NIMR (Oct-)160 [90%]18 [10%]* VIDRL (Oct-)145 [93%]11 [ 7%] Total382 [87%]59 [13%] H3 low reactors in HI assays in WHOCCs * 0% by virus neutralization

Vaccine virus

March-July 2009

By NIMR

By NIID

Vaccine virus

By Cambridge Univ.

H3N2 viruses - Summary Oct 2008-Feb 2009 H3N2 viruses co-circulated with H1N1 and B viruses in many countries Majority were antigenically similar to A/Brisbane/10/07 and A/Uruguay/716/07 by HI tests with turkey RBCs or guinea pig RBCs. The ‘low reactors’ were antigenically indistinguishable from vaccine viruses by Neutralization tests. HA and NA sequences fairly homogeneous and fell within the A/Brisbane/10/07 clade M2 sequences possessed S31N mutation, indicative of amantadine resistance Sensitive to oseltamivir and zanamivir Mar - July 2009 Majority were antigenically similar to vaccine viruses. An increasing number of H3N2 isolates have been shown to be antigenically distinct from vaccine viruses and related to A/Hawaii/7/09, A/HK/1985/09 and A/Perth/16/09. The majority of HA sequences of those viruses formed a separate clade characterized by aa subsitutions E62K, N144K, K158N and N18K. They retained resistance to amantadine/rimantadine and were sensitive to oseltamivir and zanamivir.

B viruses September 2008-January 2009

B, Sept 2008 – Jan 2009

Numbers of 2 lineages of B viruses detected in GISN since week B-Victoria lineage B-Yamagata lineage

HI reactions of influenza type B viruses By NIID

HI reactions of influenza type B viruses B/Victoria-lineage By NIMR

HI reactions of influenza type B viruses B/Yamagata lineage By NIMR

Victoria Yamagata CDC (Oct-)71 [60%]48 [40%] low reactors (77%) (23%) NIID (Oct-)18 [40%] 27[60%] Low reactors (94%) (67%) NIMR 17 [44%] 22[56%] Low reactors (76%) (14%) VIDRL (Oct-)340 [67%]167 [33%] Low reactors (94%) (62%) Total446 [63%] 264 [37%] Low reactors (91%) (51%) B low reactors in HI assays in WHOCCs

10 nucleotides B/Brisbane/60/2008-like Evolutionary Relationships Among Influenza B (Victoria Lineage) HA Genes B/Malaysia/2506/2004 K165N Chinese clade By Melbourne C.

Evolutionary Relationships Among Influenza B (Yamagata Lineage) HA Genes 10 nucleotides By Melbourne C.

March-July 2009

By NIMR HI reactions of influenza type B viruses B/Victoria-lineage

By CDC

By Cambridge Univ.

B/Victoria-lineage HA By NIID Vaccine virus Chinese viruses

By CDC B/Yamagata-lineage HA Vaccine virus

Summary for influenza B viruses Oct 2008-Feb 2009 Influenza B viruses circulated in many countries however regional outbreaks were limited. Viruses of both B/Victoria/2/87 and B/Yamagata/16/88 lineages continued to co-circulate in many countries B/Victoria-lineage viruses predominated in most countries and were mostly antigenically closely related to B/Brisbane/60/2008. Viruses mainly from China fell into a separate phylogenetic clade B/Yamagata-lineage viruses were antigenically closely related to B/Florida/4/2006 & B/Brisbane/3/2007 vaccine viruses. Three phylogenetic clades were apparent but were antigenically indistinguishable. Mar - July 2009 B/Victoria-lineage viruses predominated and were mostly antigenically closely related to vaccine strain B/Brisbane/60/2008. Many viruses isolated in China were closely related to B/Fujian Gulou/1272/08 and B/Hubei-Songzi/51/08. B/Yamagata-lineage viruses were antigenically closely related to B/Florida/4/2006 and mostly fell into their HA sequences of the B/Bagladesh/3333/07 clade.

WHO Collaborating Centers ( US-CDC, NIMR, Melbourne ) Cambridge University NICs (China-CDC, Korea-CDC, NHL-Myanmar, NCLE-Lao PDR, NIH-Mongolia and other NICs of WHO GISN) Taiwan-CDC Local PHLs in Japan Acknowledgement